Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDEXX LaboratoriesHAM:IX1 -2.82%96 3-Year EBITDA Growth Rate is 15.90% as of Jun. 2026, which is at its 10-year median of 15.90. GuruFocus rates HAM:IX1 with a GF Score™ of 96/100 and a GF Value™ of €544.63 (Modestly Undervalued). Among 165 Medical Diagnostics & Research companies, IDEXX Laboratories ranks better than 56.36% on this metric.
During the past 12 months, IDEXX Laboratories's average EBITDA Per Share Growth Rate was 18.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 15.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 13.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 16.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of IDEXX Laboratories was 96.90% per year. The lowest was -31.50% per year. And the median was 15.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
IDEXX Laboratories 3-Year EBITDA Growth Rate Related Terms
HAM:IX1 vs A, NTRA, WAT: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, IDEXX Laboratories's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 15.90% mean?
IDEXX Laboratories (HAM:IX1) has a 3-Year EBITDA Growth Rate of 15.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for IDEXX Laboratories and its competitors. This is near median its historical median of 15.90. According to the industry distribution chart, IDEXX Laboratories ranks #72 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 43.6%.
Is IDEXX Laboratories' 3-Year EBITDA Growth Rate too high?
IDEXX Laboratories' current 3-Year EBITDA Growth Rate of 15.90% is near median its 10-year median of 15.90. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.50. IDEXX Laboratories' value of 15.90% is 38.3% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #72 out of 165 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' 3-Year EBITDA Growth Rate compare to A and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #72 out of 165 companies for 3-Year EBITDA Growth Rate. This puts IDEXX Laboratories in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.50. IDEXX Laboratories' value of 15.90% is 38.3% above this benchmark. While the company's 10-year median is 15.90 vs. the industry median of 11.50, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.50, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current 3-Year EBITDA Growth Rate of 15.90% is 38.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current 3-Year EBITDA Growth Rate is 15.90%, which is near median its own 10-year median of 15.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (HAM:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €544.63, compared to a current price of €489.00 — trading 10.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 15.90%, which is near median its 10-year median of 15.90 and 38.3% above the Medical Diagnostics & Research industry median of 11.50. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For IDEXX Laboratories (HAM:IX1), the current 3-Year EBITDA Growth Rate is 15.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (HAM:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €489.00 is trading 10.2% below its estimated GF Value™ of €544.63.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for HAM:IX1:
3-Year EBITDA Growth Rate: 15.90% (near median its 10-year median of 15.90)
GF Value™: €544.63 vs. price of €489.00 (10.2% below fair value)
Industry Position: 38.3% above the Medical Diagnostics & Research median (#72 of 165)
No single metric tells the full story. See the HAM:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for HAM:IX1
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IX1 has been successfully added to your 
